Ratings by Goldman Sachs (Andrea Tan)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/27/2022 | Insmed | INSM | New Coverage | Buy (N/A) |
23.56 (19.72) |
-16.3% | Details | |
| 4/27/2022 | Vor Biopharma, Inc. | VOR | New Coverage | Neutral (N/A) |
5.64 (4.97) |
-11.88% | Details | |
| 2/24/2022 | Kodiak Sciences Inc. | KOD | Maintain | Neutral (N/A) |
|
Details | ||
| 2/11/2022 | Codiak Biosciences Inc. | CDAK | New Coverage | Buy (N/A) |
5.34 (2.88) |
-46.07% | Details | |
| 2/11/2022 | Kodiak Sciences Inc. | KOD | New Coverage | Neutral (N/A) |
65.23 (7.64) |
-88.29% | Details | |
| 2/11/2022 | Centessa Pharmaceuticals | CNTA | New Coverage | Neutral (N/A) |
10.78 (4.87) |
-54.82% | Details | |
| 5/20/2021 | Relmada Therapeutics Inc | RLMD | New Coverage | Buy (N/A) |
35.43 (18.99) |
-46.4% | Details | |
| 5/20/2021 | Madrigal Pharmaceuticals | MDGL | New Coverage | Buy (N/A) |
133.48 (71.58) |
-46.37% | Details |
